JGC
RLAY icon

J. Goldman & Co’s Relay Therapeutics RLAY Stock Holding History

J. Goldman & Co’s Portfolio RLAY Stock Details RLAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-67,600
Closed -$572K – 848
2025
Q4 		$572K Buy
+67,600
New +$482K 0.02% 445

Other funds holding RLAY

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

J. Goldman & Co's RLAY Position: Q2 2026 in Review

J. Goldman & Co reduced its Relay Therapeutics (RLAY) stake by 11% in Q2 2026, selling an estimated $103K and leaving 56,569 shares worth $1.06M. The position accounts for 0.03% of the portfolio, ranked #447.

J. Goldman & Co first reported a position in RLAY in Q4 2025 and has held it in 3 quarters since. 259 funds tracked by Wall St. Rank hold RLAY as of Q2 2026.

  • J. Goldman & Co held 56,569 shares of Relay Therapeutics worth $1.06M as of Q2 2026.
  • J. Goldman & Co sold 7,068 Relay Therapeutics shares in Q2 2026, an estimated $103K.
  • Relay Therapeutics made up 0.03% of J. Goldman & Co's portfolio in Q2 2026, its #447 holding.
  • J. Goldman & Co first reported a position in Relay Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 259 funds tracked by Wall St. Rank held Relay Therapeutics as of Q2 2026.

Based on J. Goldman & Co's 13F filing for Q2 2026, filed 14 Aug 2026.